The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease
Open accessAbstract
Objective: Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely understood. RBD and cholinergic system degeneration are identified independently as risk factors for cognitive impairment in PD. We aimed to assess the association between cholinergic denervation and symptoms of RBD in PD patients without dementia. Methods: Eighty subjects with PD without dementia (age, 64.6 ± 7.0 years; range, 50–82 years; 60 males, 20 females; mean Montreal Cognitive Assessment Test [MoCA] score, 26.2 ± 2.1; range 21–30) underwent clinical assessment, neuropsychological testing, and [ 11 C]methylpiperidyl propionate acetylcholinesterase and [ 11 C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 positron emission tomography (PET) imaging. 11 C3‐Amino‐4‐(2‐dimethylaminomethyl‐phenylsulfaryl)‐benzonitrile (DASB) serotonin transporter PET imaging was performed in a subset of 35 subjects. The presence of RBD symptoms was determined using the Mayo Sleep Questionnaire. Results: Twenty‐seven of 80 subjects (33.8%) indicated a history of RBD symptoms. Subjects with and without RBD symptoms showed no significant differences in age, motor disease duration, MoCA, Unified Parkinson Disease Rating Scale motor scores, or striatal DTBZ binding. Subjects with RBD symptoms, in comparison to those without, exhibited decreased neocortical, limbic cortical, and thalamic cholinergic innervation (0.0213 ± 0.0018 vs 0.0236 ± 0.0022, t = 4.55, p < 0.0001; 0.0388 ± 0.0029 vs 0.0423 ± 0.0058, t = 2.85, p = 0.0056; 0.0388 ± 0.0025 vs 0.0427 ± 0.0042, t = 4.49, p < 0.0001, respectively). Brainstem and striatal DASB binding showed no significant differences between groups. Interpretation: The presence of RBD symptoms in PD is associated with relative neocortical, limbic cortical, and thalamic cholinergic denervation although not with differential serotoninergic or nigrostriatal dopaminergic denervation. The presence of RBD symptoms may signal cholinergic system degeneration. ANN NEUROL 2012;
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · cited 1×
“Montreal Cognitive Assessment (MoCA) scores <20 were excluded.(15) The mean MoCA score was 26.”
BackgroundStudies of interference in serial verbal reactions
Stroop, J. R. (1935) · Journal of Experimental Psychology · doi:10.1037/h0054651 · Cited by 18,622
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · cited 1×
“5, and 12 in H-Y stage 3.(14) The mean duration of disease was 6.”
BackgroundStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationDistribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
Goetz, C. G., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stebbins, G. T., Stern, M. B., Tilley, B. C., Dodel, R., Dubois, B., et al. (2007) · Movement Disorders · doi:10.1002/mds.21198 · Cited by 1,404
Chronic Behavioral Disorders of Human REM Sleep: A New Category of Parasomnia
Schenck, C. H., Bundlie, S. R., Ettinger, M. G., & Mahowald, M. W. (1986) · Sleep · doi:10.1093/sleep/9.2.293 · Cited by 1,150
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., et al. (2009) · Brain · doi:10.1093/brain/awp245 · Cited by 965
Cited by
Boeve, B. F., Silber, M. H., Ferman, T. J., Lin, S. C., Benarroch, E. E., Schmeichel, A. M., Ahlskog, J. E., Caselli, R. J., Jacobson, S., Sabbagh, M., et al. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.015 · Cited by 393
Health‐related quality of life in early Parkinson's disease: The impact of nonmotor symptoms
Duncan, G. W., Khoo, T. K., Yarnall, A. J., O'Brien, J. T., Coleman, S. Y., Brooks, D. J., Barker, R. A., & Burn, D. J. (2014) · Movement Disorders · doi:10.1002/mds.25664 · Cited by 382
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Chahine, L. M., Amara, A. W., & Videnovic, A. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.08.001 · Cited by 333
Hall, H., Reyes, S., Landeck, N., Bye, C., Leanza, G., Double, K., Thompson, L., Halliday, G., & Kirik, D. (2014) · Brain · doi:10.1093/brain/awu193 · Cited by 302
Cholinergic Dysfunction in Parkinson’s Disease
Müller, M. L. T. M., & Bohnen, N. I. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0377-9 · Cited by 264
Self-citationMotor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Bedard, M.-A., Aghourian, M., Legault-Denis, C., Postuma, R. B., Soucy, J.-P., Gagnon, J.-F., Pelletier, A., & Montplaisir, J. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2018.12.020 · Cited by 123
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018) · Movement Disorders · doi:10.1002/mds.27386 · Cited by 121
“(11)C-PMP PET has shown that RBD in PD patients is also associated with cholinergic system degeneration in neocortical, limbic cortical, and thalamic areas.(93)”
BackgroundChemosensory dysfunction in neurodegenerative diseases
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63855-7.00020-4 · Cited by 78
Optimal Treatment of Depression and Anxiety in Parkinson's Disease
Pontone, G. M., & Mills, K. A. (2021) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.02.037 · Cited by 67
Ray, N. J., & Strafella, A. P. (2012) · Movement Disorders · doi:10.1002/mds.25173 · Cited by 35
“with cholinergic degeneration.(52) A recent study also found that nondemented PD patients with evidence of cholinergic function significantly below the level of healthy controls had worse global cognitive scores than those with healthy AChE activity.”
Trends in glycolipid biomarker discovery in neurodegenerative disorders by mass spectrometry
Dehelean, L., Sarbu, M., Petrut, A., & Zamfir, A. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_42 · Cited by 16
Metadata
- Authors
- Kotagal, V., Albin, R. L., Müller, M. L. T. M., Koeppe, R. A., Chervin, R. D., Frey, K. A., & Bohnen, N. I.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-04
- Volume
- 71
- Issue
- 4
- Pages
- 560-568
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2004103828
- Cited by
- 253
- References
- 57
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.